A cost-effectiveness analysis of domestic radon remediation in four primary care trusts located in Northamptonshire, UK

Health Policy

Volumn 71, Issue 1, 2005, Pages 43-56

  Coskeran, Thomas ^a   Denman, Antony ^b   Phillips, Paul ^c   Tornberg, Roger ^d  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b NORTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NORTHAMPTON   (United Kingdom)

^d Radon Centres Ltd   (United Kingdom)

Author keywords

Cost effectiveness; Lung cancer; Primary care trusts; Radon remediation

Indexed keywords

RADON;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH PROGRAM; HUMAN; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; PRIMARY MEDICAL CARE; RISK ASSESSMENT; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; ENGLAND; HOUSING; HUMANS; LUNG NEOPLASMS; PRIMARY HEALTH CARE; RADON; STATE MEDICINE;

EID: 9644276992     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2004.05.003     Document Type: Article

References (39)

1. Lubin J., Boice J.D. Lung cancer risk from residential radon: a meta-analysis of eight epidemiological studies. Journal of the National Cancer Institute. 89(1):1997;49-57
2. Darby S., Whitley E., Silcocks P., Thakrar B., Green M., Lomas P., et al. Risk of lung lancer associated with residential radon exposure in South-West England: a case-control study. British Journal of Cancer. 78:1998;394-408
3. Kreienbrock L., Kreuzer M., Gerken M., Dingerkus G., Wellmann J., Keller G., et al. Case-control study on lung-cancer and residential radon in Western Germany. Am. J. Epidemiol. 153:2001;42-52
4. Darby S., Hill R., Doll R. Radon: a likely carcinogen at all exposures. Annals of Oncology. 12:2002;1341-1451
5. Phillips P.S., Denman A.R. Radon: a human carcinogen. Science Progress. 80(1):1997;1-17
6. National Research Council. Health Effects of Exposure to Radon BEIR VI. Washington, DC: National Academy Press; 1999.
7. Green, BMR, Miles, JCH, Bradley, EJ, Rees, DM. Radon Atlas of England and Wales. Chilton: NRPB-W26; 2002.
8. Phillips P.S., Fraser J.D., Denman A.R. Effectiveness of secondary radon protection in Northamptonshire houses. Environmental Management and Health. 11(4):2000;337-352
9. Bradley EJ, Lomas PR, Green BMR, Smithard J. Radon in dwellings in England: 1997 review. National Radiological Protection Board Report R293. Oxfordshire (UK): Didcot; 1997.
10. Denman A.R., Phillips P.S. A review of the cost effectiveness of radon mitigation in domestic properties in Northamptonshire. Journal of Radiological Protection. 18:1998;119-124
11. Ryan D., Kelleher C.C. A survey of householders' mitigation strategy. European Journal of Public Health. 9(1):1999;62-64
12. Eunkyung P., Scherer C., Glynn C.J. Community involvement and risk perception at personal and societal levels. Health, Risk and Society. 3(3):2001;281-292
13. Warner K.E., Courant P.N., Mendez D. Effects of residential mobility on individual versus population risk of radon-related lung cancer. Environmental Health Perspectives. 103(12):1995;1144-1149
14. Warner K.E., Mendez D., Courant P.N. Towards a more realistic appraisal of the lung cancer risk from radon: the effects of residential mobility. American Journal of Public Health. 86(9):1996;1222-1227
15. Abelson P. Radon today: the role of flimflam in public policy. Regulation. 14(4):1991;95-100
16. Peterson M., Homes U.S. Management Science. 42:1996;1476-1492
17. Cohen B. Problems in the radon vs. lung cancer test of the linear no-threshold theory and a procedure for resolving them. Health Physics. 68(2):1997;157-174
18. Coskeran T., Denman A.R., Phillips P.S., Gillmore G. A critical comparison of the cost-effectiveness of domestic radon remediation programmes in three counties of England. Journal of Environmental Radioactivity. 62:2002;129-194
19. Denman AR, Phillips PS, Tornberg R, Groves-Kirby CJ. Analysis and Assessment of the Individual Health Benefits accruing from a Domestic Radon Remediation Programme. Journal of Environmental Radioactivity; forthcoming 2004.
20. Department for Environment. Food and Rural Affairs. Radon Good Practice Guide, London, PB 7933; 2000.
21. The Radon Council Ltd. A guide to the requirements for the detection and measurement of natural radon levels associated with remedial measures and subsequent monitoring of results. In: The Radon Manual. London, UK; 1995.
22. Briggs D.J., Denman A.R., Gulliver J., Marley R.F., Kennedy C.A., Phillips P.S., et al. Time-activity modelling of domestic exposures to radon. Journal of Environmental Management. 67(2):2003;107-120
23. Bradley EJ. Responses to radon remediation advice. In: Proceedings of the Ninth International Congress of International Radiation Protection Association 4-798-4-800; 1996.
24. National Radiological Protection Board. Estimates of late radiation risks to the UK population. Documents of the NRPB, vol. 4(4). Chilton, UK; 1993.
25. Kennedy C.A., Gray A.M., Denman A.R., Phillips P.S. A cost effectiveness analysis of a residential radon remediation programme in the United Kingdom. British Journal of Cancer. 81:1999;243-247
26. Her Majesty's Treasury. The Green Book: Appraisal and Evaluation in Central Government. London: The Stationery Office; 2003.
27. Naismith S., Miles J.C.H., Scivyer C.R. The influence of house characteristics on the effectiveness of radon remedial measures. Health Physics. 75(4):1998;410-416
28. Gerber A., Phelps C. Economic foundations of cost-effectiveness analysis. Journal of Health Economics. 16:1997;1-31
29. Office for National Statistics. Regional Trends, vol. 37. London (UK): Office for National Statistics, The Stationery Office; 2002.
30. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. British Medical Journal. 323:2001;1300-1303
31. Thomas A, Hobson J. Review and evaluation of the radon remediation pilot programme. Transport and the Regions Report no. DETR/RAS/00.004. London (UK): Department of the Environment; 2000.
32. Mendez D., Warner K.E., Courant P.N. Effects of radon mitigation vs. smoking cessation in reducing radon-related risk of lung cancer. American Journal of Public Health. 88(5):1998;811-812
33. Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Health Technology Assessment 2001;5(32).
34. Wake BL, Taylor RS, Sandercock J. Hyperfractionated/accelerated radiotherapy regimens for the treatment of non-small cell lung cancer. A systematic review of clinical and cost-effectiveness. Birmingham: Department of Public Health and Epidemiology, University of Birmingham; January 2002.
35. Coyle D., Drummond M. Costs of conventional radical radiotherapy versus continuous hyperfractionated accelerated radiotherapy (CHART) in the treatment of patients with head and neck cancer or carcinoma of the Bronchus. Clinical Oncology. 9:1997;313-321
36. Baldwin G., Frank E., Fielding B. US women physicians' residential radon testing practices. American Journal of Preventive Medicine. 15(1):1998;49-53
37. Lee M., Lichtenstein E., Andrews J.A., Glasgow R.E., Hampson S.E. Radon-smoking synergy: a population-based behavioral risk reduction approach. Preventive Medicine. 29:1999;222-227
38. Buck D, Godfrey C, Parrott S, Raw M. Cost effectiveness of smoking cessation interventions. London: Health Education Authority; 1997.
39. Denman A.R., Groves-Kirby C.J., Phillips P.S., Tornberg R. Using the European Community Radon Software to estimate the individual health benefits of a domestic radon remediation programme. Journal of Radiological Protection. 24(1):2004;83-90